Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM TETRADECYL SULFATE vs DEHYDRATED ALCOHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins,Treatment of small varicose veins (off-label for larger varicose veins)
FDA-approved for adjunctive therapy in the treatment of cystic thyroid nodules,Off-label: Neurolysis for celiac plexus block in pancreatic cancer pain,Off-label: Ablation of hepatocellular carcinoma,Off-label: Sclerotherapy for esophageal varices
1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.
Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
2-4 hours in most individuals at zero-order kinetics; terminal half-life is concentration-dependent due to saturation of alcohol dehydrogenase. Clinically, elimination rate is constant at 15-20 mg/d L/hour in non-tolerant individuals.
Not extensively metabolized; primarily eliminated unchanged by the kidneys.
Primarily hepatic via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH); minor metabolism via CYP2E1 at high concentrations.
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Ethanol is primarily eliminated by hepatic metabolism (90-98%) via alcohol dehydrogenase and aldehyde dehydrogenase, with 2-10% excreted unchanged in urine, breath, and sweat. Renal elimination is minor and variable.
Approximately 50% bound to plasma proteins (albumin and globulins).
Negligible (<5%); no specific binding proteins.
0.2–0.3 L/kg, indicating distribution primarily within extracellular fluid and plasma volume.
0.5-0.7 L/kg, approximating total body water. Higher in females due to lower lean body mass.
Intravenous: 100% (direct intravascular administration). Oral: negligible due to extensive degradation and poor absorption.
Oral: ~80-100% due to rapid absorption from stomach and small intestine; IV: 100%.
No dose adjustment required for renal impairment.
No dosage adjustment required for renal impairment.
Use with caution in Child-Pugh class C; no specific dose adjustment defined.
No specific Child-Pugh-based adjustments; use with caution in severe hepatic dysfunction due to potential accumulation.
0.1-0.3 m L of 1% solution per injection, repeated as needed; maximum 5 m L per session.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific adjustment; use lowest effective dose due to potential increased sensitivity.
No specific dose adjustment; use with caution due to age-related comorbidities and potential for increased sensitivity.
None.
No FDA boxed warning exists for dehydrated alcohol. However, it should only be administered by physicians experienced in injection techniques for specific indications due to risk of tissue necrosis and nerve damage.
Anaphylactic shock and severe allergic reactions have been reported.,Intra-arterial injection can cause severe necrosis or ischemia.,Extravasation may cause pain and tissue necrosis.,Use caution in patients with underlying arterial disease or hypercoagulable states.,Thromboembolic events including deep vein thrombosis and pulmonary embolism have been reported.
Risk of tissue necrosis and sloughing if extravasation occurs,Neurological injury if injected near nerves (e.g., peripheral nerve damage, paralysis),Hypotension and bradycardia during celiac plexus block,Alcohol intoxication and CNS depression if absorbed systemically,Use with caution in patients with liver disease or diabetes mellitus
Known hypersensitivity to sodium tetradecyl sulfate or any component of the formulation,Acute thromboembolic disease,Severe peripheral arterial disease,Valvular incompetence of the deep venous system,Uncontrolled systemic disease (e.g., diabetes, thyroid disorders),Local infection or inflammation at the injection site
Hypersensitivity to ethanol or any component of the formulation,Acute infection at the injection site,Uncorrectable coagulation abnormalities,Pregnancy (relative contraindication due to fetal alcohol spectrum disorders)
No specific food interactions have been reported with sodium tetradecyl sulfate. However, maintaining adequate hydration is recommended. Avoid excessive alcohol intake, as it may exacerbate venous insufficiency.
No specific food interactions. However, avoid alcohol consumption for 24 hours post-procedure due to risk of additive CNS depression.
Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack of safety data, especially in the first trimester. Theoretical risk of placental transfer is low due to high molecular weight and local administration. No reported fetal anomalies.
First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) with high systemic exposure. Second trimester: Continued risk for growth restriction and neurodevelopmental abnormalities. Third trimester: Risk of growth retardation, preterm birth, and neurobehavioral deficits. Avoid systemic use; local injection for nerve block or ablation has minimal systemic absorption but caution advised.
No data on excretion into human milk. M/P ratio unknown. Due to local administration and rapid metabolism, systemic exposure is minimal. Caution advised; consider discontinuing breastfeeding or avoiding use in lactating women.
Alcohol is excreted into breast milk; M/P ratio approximately 1.0. Chronic ingestion can impair infant motor development. Dehydrated alcohol for therapeutic injection likely results in negligible systemic levels; however, avoid breastfeeding immediately after procedure. Advise discarding milk for 2-3 hours post-procedure.
No specific dose adjustments recommended. Use only if clearly needed, with smallest effective volume and concentration. Physiological changes in pregnancy (increased plasma volume, altered coagulation) may affect response but no pharmacokinetic data exist.
No dose adjustment needed for localized injection; pharmacokinetics of ethanol unchanged in pregnancy. Avoid use as systemic agent; use alternative if possible.
Sodium tetradecyl sulfate is a sclerosing agent used for the treatment of varicose veins and telangiectasias. It works by causing endothelial damage and subsequent fibrosis of the vein. Use with caution in patients with a history of deep vein thrombosis, pulmonary embolism, or hypercoagulable states. Allergic reactions, including anaphylaxis, have been reported; a test dose is recommended. Avoid extravasation as it may cause tissue necrosis. Compression stockings should be applied post-injection to enhance efficacy and reduce complications.
Absolute ethanol (dehydrated alcohol) is used for neurolysis in celiac plexus block for pancreatic cancer pain and for ablation of certain soft tissue lesions. Administer slowly to avoid local toxicity. Inadvertent intravascular injection can cause immediate pain and tissue necrosis. Use ultrasound or CT guidance for accurate placement. Monitor for hypotension, pain, and transient alcohol intoxication. Contraindicated in patients with bleeding disorders or local infection.
This medication is injected directly into your varicose veins to cause them to scar and close.,You may experience temporary bruising, pain, or redness at the injection site.,It is normal for the treated veins to feel hard and lumpy for a few weeks after treatment.,You will need to wear compression stockings for several days to weeks as directed by your healthcare provider.,Avoid sun exposure to the treated area until bruising resolves to reduce the risk of hyperpigmentation.,Seek immediate medical attention if you experience signs of an allergic reaction, chest pain, or difficulty breathing.,Do not discontinue prescribed blood thinners unless instructed by your doctor, as the risk of bleeding may be increased.
You may feel a temporary burning sensation at the injection site.,This medication is used to block pain signals from certain nerves.,Avoid alcohol consumption for 24 hours after the procedure to prevent additive effects.,Report any severe pain, bleeding, or signs of infection to your healthcare provider.,You may experience temporary dizziness or lightheadedness after the injection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM TETRADECYL SULFATE vs DEHYDRATED ALCOHOL, answered by our medical review team.
SODIUM TETRADECYL SULFATE is a Sclerosing Agent that works by Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.. DEHYDRATED ALCOHOL is a Sclerosing agent that works by Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM TETRADECYL SULFATE and DEHYDRATED ALCOHOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM TETRADECYL SULFATE is: 1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.. The standard adult dose of DEHYDRATED ALCOHOL is: Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM TETRADECYL SULFATE and DEHYDRATED ALCOHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM TETRADECYL SULFATE is classified as Category C. Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack. DEHYDRATED ALCOHOL is classified as Category C. First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) wit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.